Sangamo Biosciences Inc (NASDAQ:SGMO) Q4 2017 Sentiment Report

May 17, 2018 - By Ann Prendergast

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Logo

Sentiment for Sangamo Biosciences Inc (NASDAQ:SGMO)

Sangamo Biosciences Inc (NASDAQ:SGMO) institutional sentiment decreased to 1.4 in Q4 2017. Its down -0.17, from 1.57 in 2017Q3. The ratio turned negative, as 81 active investment managers increased or opened new holdings, while 58 sold and trimmed stakes in Sangamo Biosciences Inc. The active investment managers in our partner’s database now hold: 53.22 million shares, up from 51.93 million shares in 2017Q3. Also, the number of active investment managers holding Sangamo Biosciences Inc in their top 10 holdings increased from 3 to 4 for an increase of 1. Sold All: 16 Reduced: 42 Increased: 46 New Position: 35.

Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company has market cap of $1.64 billion. The companyÂ’s proprietary zinc finger DNA-binding protein technology enables specific genome editing and gene regulation. It currently has negative earnings. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off.

The stock increased 0.62% or $0.1 during the last trading session, reaching $16.2. About 1.59 million shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 352.38% since May 17, 2017 and is uptrending. It has outperformed by 340.83% the S&P500.

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on August, 8. They expect $-0.11 earnings per share, up 35.29 % or $0.06 from last year’s $-0.17 per share. After $-0.23 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -52.17 % EPS growth.

Sanctuary Wealth Advisors Llc holds 3.64% of its portfolio in Sangamo Therapeutics, Inc. for 268,418 shares. Opaleye Management Inc. owns 580,000 shares or 3.05% of their US portfolio. Moreover, Alexandria Capital Llc has 2.21% invested in the company for 925,527 shares. The New York-based Iguana Healthcare Management Llc has invested 1.6% in the stock. Bogle Investment Management L P De, a Massachusetts-based fund reported 966,128 shares.

Since January 1, 0001, it had 0 insider buys, and 16 insider sales for $2.64 million activity.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Ratings Coverage

Ratings analysis reveals 80% of Sangamo Therapeutics’s analysts are positive. Out of 5 Wall Street analysts rating Sangamo Therapeutics, 4 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $8.0 while the high is $33.0. The stock’s average target of $23.25 is 43.52% above today’s ($16.2) share price. SGMO was included in 6 notes of analysts from November 22, 2017. Piper Jaffray maintained the stock with “Buy” rating in Wednesday, January 3 report. The stock has “Buy” rating by Wells Fargo on Thursday, February 22. The stock has “Buy” rating by Jefferies on Thursday, February 22. The firm has “Buy” rating given on Thursday, February 22 by Piper Jaffray. Wedbush maintained the shares of SGMO in report on Tuesday, March 13 with “Hold” rating.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Seekingalpha.com which released: “Genomic Medicine: Catch The Gene Therapy Wave” on May 14, 2018, also Seekingalpha.com with their article: “Sangamo Therapeutics’ (SGMO) CEO Sandy Macrae on Q1 2018 Results – Earnings Call Transcript” published on May 08, 2018, Streetinsider.com published: “Sangamo Therapeutics (SGMO) & Sanofi (SNY) Company, Bioverativ Inc., Report FDA Acceptance of IND Application …” on May 16, 2018. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Seekingalpha.com and their article: “Sangamo: The Secondary Was Ill-Timed Or Not” published on May 08, 2018 as well as Fool.com‘s news article titled: “Sangamo Therapeutics Stock History” with publication date: May 17, 2018.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: